Press Releases

Company News
Summary ToggleAcura Pharmaceuticals to Host 2014 Financial Results Conference Call on March 3, 2015
Feb 23, 2015
PALATINE, IL -- (Marketwired) -- 02/23/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for 2014 following the close of financial markets on Monday, March 2,

Read more

Summary ToggleAcura Pharmaceuticals Initiates Clinical Study of Meth-Resistant Nexafed(R) Extended-Release Formulations
Feb 16, 2015

Products Employ Improved Impede(R) 2.0 Technology

Read more

Summary ToggleAcura Pharmaceuticals Expands Meth-Resistant Decongestant Line With NEXAFED(R) Sinus Pressure + Pain
Feb 05, 2015

New Combination Sinus Pain and Congestion Product Will Utilize NEXAFED's IMPEDE(R) Meth-Deterring Technology

Read more

Summary ToggleAcura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
Jan 08, 2015
PALATINE, IL -- (Marketwired) -- 01/08/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR)  today announced that the Company has entered into a Collaboration and License Agreement (the "Agreement") with Egalet US, Inc. and Egalet Ltd. (together "Egalet", subsidiaries of Egalet Corporation (NASDAQ:

Read more

Summary ToggleAcura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy
Dec 23, 2014
PALATINE, IL -- (Marketwired) -- 12/23/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine hydrochloride (HCl)], Acura's next generation pseudoephedrine with methamphetamine-resistant IMPEDE

Read more

Summary ToggleAcura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations
Dec 08, 2014

First Patent Encompassing the IMPEDE(R) Technology

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2014 Financial Results
Nov 03, 2014
PALATINE, IL -- (Marketwired) -- 11/03/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2014 .

Read more

Summary ToggleAcura Pharmaceuticals to Host Third Quarter 2014 Financial Results Conference Call on November 4, 2014
Oct 28, 2014
PALATINE, IL -- (Marketwired) -- 10/28/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the third quarter 2014 following the close of financial markets on

Read more

Summary ToggleAcura Pharmaceuticals Provides Update on Its Hydrocodone Bitartrate With Acetaminophen Tablets Development
Oct 16, 2014
PALATINE, IL -- (Marketwired) -- 10/16/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR)  announced today that the US Food and Drug Administration (FDA) has denied on procedural grounds Acura's appeal of the position taken by Division of Anesthesia , Analgesia, and Addiction Products (DAAAP) that

Read more

Summary ToggleAcura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints
Sep 29, 2014
PALATINE, IL -- (Marketwired) -- 09/29/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today preliminary results from three clinical studies for its abuse deterrent AVERSION® hydrocodone bitartrate with acetaminophen (AVERSION H/A) development product with the key study demonstrating

Read more

Summary ToggleAcura Pharmaceuticals Submits Formal Dispute Resolution Request With FDA Regarding Hydrocodone Bitartrate With Acetaminophen Tablets
Sep 15, 2014
PALATINE, IL -- (Marketwired) -- 09/15/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has submitted a formal dispute resolution request with the FDA for Vycavert®, its abuse deterrent formulation of hydrocodone and acetaminophen tablets.

Read more

Summary ToggleAcura Pharmaceuticals Receives Grant From National Institutes of Health to Fund Limitx(TM) Novel Abuse Deterrent Technology
Aug 27, 2014
PALATINE, IL -- (Marketwired) -- 08/27/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has been awarded a $300,000 grant (the "Grant") by the National Institute On Drug Abuse ("NIDA") of the National Institutes of Health to fund Phase I development of Acura's new, early

Read more

Summary ToggleAcura Pharmaceuticals Provides Update on FDA Discussions Surrounding Development of Aversion Hydrocodone With Acetaminophen Tablet
Aug 15, 2014
PALATINE, IL -- (Marketwired) -- 08/15/14 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today preliminary discussions from a meeting held with the U.S. Food and Drug Administration (FDA) regarding the development pathway for Acura's AVERSION® hydrocodone with acetaminophen tablet

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2014 Financial Results
Aug 04, 2014
PALATINE, IL -- (Marketwired) -- 08/04/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and six months ended June 30, 2014 .

Read more

Summary ToggleAcura Pharmaceuticals to Host Second Quarter 2014 Financial Results Conference Call on August 5, 2014
Jul 24, 2014
PALATINE, IL -- (Marketwired) -- 07/24/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the second quarter 2014 following the close of financial markets on

Read more

Summary ToggleAcura Pharmaceuticals Provides Update on Its Abuse Deterrent Hydrocodone/Acetaminophen Combination Drug
May 27, 2014
PALATINE, IL -- (Marketwired) -- 05/27/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced the US Food and Drug Administration (FDA) advised the Company that the data from our intranasal abuse liability study AP-ADF-301 (Study 301) for our AVERSION hydrocodone bitartrate with

Read more

Summary ToggleAcura Pharmaceuticals Announces Settlement of Patent Litigation With Sandoz Inc.
May 21, 2014
PALATINE, IL -- (Marketwired) -- 05/21/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into a Settlement Agreement with Sandoz Inc.

Read more

Summary ToggleAcura Pharmaceuticals Announces Settlement of Patent Litigation With Ranbaxy Inc.
May 08, 2014
PALATINE, IL -- (Marketwired) -- 05/08/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into a Settlement Agreement with Ranbaxy Inc.

Read more

Displaying 55 - 72 of 135 results